Holdofeb (Paracetamol)

Holdofeb is indicated for the temporary relief of common conditions that cause fever or pain. It may be used as part of a broader symptomatic treatment plan when non‑opioid analgesia is appropriate.

• Fever associated with infections, inflammatory conditions, or post‑vaccination reactions.
• Mild to moderate headache, including tension‑type and migraine onset.
• Dental pain, such as after tooth extraction or orthodontic adjustments.
• Musculoskeletal discomfort, including minor sprains, strains, or backache.
• Menstrual cramps and other mild visceral pain.
• Fever in children (≥2 years) when temperature exceeds 38°C (100.4°F).
• Pain from minor burns or superficial skin injuries.

• Paracetamol, the active ingredient in Holdofeb, reduces pain and fever by inhibiting the activity of cyclooxygenase enzymes in the central nervous system, particularly COX‑2, which leads to decreased synthesis of prostaglandins that sensitize pain pathways and regulate body temperature. The drug’s action is primarily central, with minimal peripheral anti‑inflammatory effects, allowing it to lower temperature set‑points in the hypothalamus and raise the pain threshold.

Like all medicines, Holdofeb may cause unwanted effects, most of which are mild and transient.

Common

• Nausea or mild stomach upset.
• Headache.
• Dizziness.
• Skin rash or mild itching.
• Transient fatigue or feeling of weakness.
• Mild abdominal discomfort.
• Mild increase in blood pressure (rare).

Serious

• Severe allergic reaction with swelling of the face, lips, or throat.
• Liver injury manifested by jaundice, dark urine, or abdominal pain.
• Blood disorders such as thrombocytopenia or neutropenia.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis (very rare).
• Acute renal failure in patients with pre‑existing kidney disease.
• Hypersensitivity reactions such as urticaria.

When using Holdofeb, certain precautions should be observed to minimize risk and ensure safe use.

• Do not exceed the recommended daily amount; chronic overuse can harm the liver.
• Avoid use in individuals with known severe liver disease or active hepatitis.
• Use caution in patients with renal impairment; dose adjustment may be needed.
• Limit alcohol consumption while taking Holdofeb, as combined use increases liver toxicity.
• Consult a healthcare professional before use during pregnancy or breastfeeding, as safety data are limited.
• Keep out of reach of children; accidental ingestion can cause serious toxicity.
• Do not combine with other paracetamol‑containing products to avoid accidental overdose.

Holdofeb can interact with other medicines, potentially altering its effectiveness or increasing the risk of adverse effects.

Avoid

• Concomitant use with other paracetamol‑containing products, which can lead to overdose and liver injury.
• Co‑administration with strong enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) that may reduce paracetamol levels.
• Use with high‑dose aspirin or other NSAIDs in patients at risk for gastrointestinal bleeding.

Use with caution

• Combination with warfarin or other anticoagulants, as paracetamol may enhance anticoagulant effect.
• Concurrent use with alcohol, especially in chronic drinkers, due to increased hepatotoxic risk.
• Administration alongside certain antiviral or antiretroviral agents (e.g., ritonavir) that can affect metabolism.